Last reviewed · How we verify

Hoffmann-La Roche — Portfolio Competitive Intelligence Brief

Hoffmann-La Roche pipeline: 51 marketed, 0 filed, 78 Phase 3, 73 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

51 marketed 0 filed 78 Phase 3 73 Phase 2 125 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Copegus (ribavirin) Copegus (ribavirin) marketed Nucleoside analog antiviral Viral RNA polymerase; IMPDH (inosine monophosphate dehydrogenase) Virology/Infectious Disease
FEC FEC marketed Combination chemotherapy regimen Oncology
enfuvirtide [Fuzeon] enfuvirtide [Fuzeon] marketed
Actos Actos marketed Other
FUZEON [enfuvirtide] FUZEON [enfuvirtide] marketed HIV fusion inhibitor gp41 (HIV envelope glycoprotein) Infectious Disease / Virology
NSAIDs NSAIDs marketed
antihistamine antihistamine marketed Other
Phesgo Phesgo marketed Other
PEG-IFN alfa-2a PEG-IFN alfa-2a marketed
rituximab [MabThera/Rituxan] rituximab [MabThera/Rituxan] marketed CD20-targeting monoclonal antibody CD20 Oncology, Immunology
Erlotinib [Tarceva] Erlotinib [Tarceva] marketed
ibandronate [Bonviva/Boniva] ibandronate [Bonviva/Boniva] marketed Bisphosphonate Farnesyl pyrophosphate synthase (indirect); hydroxyapatite in bone (binding site) Bone metabolism / Osteoporosis

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. GlaxoSmithKline · 12 shared drug classes
  2. Merck Sharp & Dohme LLC · 11 shared drug classes
  3. Pfizer · 11 shared drug classes
  4. Sanofi · 10 shared drug classes
  5. Amgen · 9 shared drug classes
  6. Assistance Publique - Hôpitaux de Paris · 8 shared drug classes
  7. AstraZeneca · 8 shared drug classes
  8. Ain Shams University · 7 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Hoffmann-La Roche:

Cite this brief

Drug Landscape (2026). Hoffmann-La Roche — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hoffmann-la-roche. Accessed 2026-05-13.

Related